Top-Rated StocksTop-RatedNASDAQ:MRUS Merus (MRUS) Stock Price, News & Analysis $50.00 -0.37 (-0.73%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$48.12▼$50.3950-Day Range$49.00▼$58.8452-Week Range$19.81▼$61.61Volume777,878 shsAverage Volume740,090 shsMarket Capitalization$2.93 billionP/E RatioN/ADividend YieldN/APrice Target$80.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Merus alerts: Email Address Merus MarketRank™ Stock AnalysisAnalyst RatingBuy3.17 Rating ScoreUpside/Downside60.4% Upside$80.20 Price TargetShort InterestBearish12.18% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$1.08 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.27) to ($3.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.42 out of 5 starsMedical Sector433rd out of 910 stocksPharmaceutical Preparations Industry194th out of 426 stocks 4.6 Analyst's Opinion Consensus RatingMerus has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMerus has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Merus' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.18% of the outstanding shares of Merus have been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Merus has recently increased by 2.44%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMerus does not currently pay a dividend.Dividend GrowthMerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MRUS. Previous Next 1.8 News and Social Media Coverage News SentimentMerus has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Merus this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for MRUS on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows1 people have added Merus to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Merus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,075,452.00 in company stock.Percentage Held by InsidersOnly 4.57% of the stock of Merus is held by insiders.Percentage Held by Institutions96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Merus' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Merus are expected to decrease in the coming year, from ($3.27) to ($3.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merus is -18.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merus is -18.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerus has a P/B Ratio of 4.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Merus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Merus Stock (NASDAQ:MRUS)Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Read More MRUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRUS Stock News HeadlinesAugust 28, 2024 | americanbankingnews.comBrokerages Set Merus (NASDAQ:MRUS) Price Target at $80.20August 27, 2024 | markets.businessinsider.comBuy Rating on Merus Backed by Strong Clinical Advantages and Market PositioningSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 15, 2024 | seekingalpha.comMerus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial RisksAugust 15, 2024 | seekingalpha.comMerus: Great European Oncology Developer, But Properly ValuedAugust 12, 2024 | theglobeandmail.comBiotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival RatesAugust 9, 2024 | finance.yahoo.comWe're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn RateAugust 7, 2024 | finance.yahoo.comMerus to Present at Canaccord Genuity’s 44th Annual Growth ConferenceSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 5, 2024 | msn.com3 Best Stocks to Buy Now, 8/5/2024, According to Top AnalystsAugust 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Merus on Strong Clinical Progress and Capital RaiseAugust 2, 2024 | markets.businessinsider.comBuy Rating on Merus Backed by Promising Petosemtamab Trials and Expanding Market PotentialAugust 1, 2024 | investorplace.comMRUS Stock Earnings: Merus Misses EPS, Misses Revenue for Q2 2024August 1, 2024 | globenewswire.comMerus Announces Financial Results for the Second Quarter 2024 and Provides Business UpdateJuly 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Merus on Promising Petosemtamab Trials and $67 Price TargetJuly 24, 2024 | globenewswire.comMerus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCCJuly 19, 2024 | money.usnews.comMerus N.VJune 3, 2024 | globenewswire.comMerus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual MeetingSee More Headlines Receive MRUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRUS CUSIPN/A CIK1651311 Webwww.merus.nl Phone(130) 253-8800FaxN/AEmployees37Year FoundedN/APrice Target and Rating Average Stock Price Target$80.20 High Stock Price Target$99.00 Low Stock Price Target$45.00 Potential Upside/Downside+60.4%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-154,940,000.00 Net Margins-476.41% Pretax Margin-460.58% Return on Equity-36.33% Return on Assets-28.68% Debt Debt-to-Equity RatioN/A Current Ratio9.97 Quick Ratio9.97 Sales & Book Value Annual Sales$35.19 million Price / Sales83.38 Cash FlowN/A Price / Cash FlowN/A Book Value$10.95 per share Price / Book4.57Miscellaneous Outstanding Shares58,688,000Free Float56,006,000Market Cap$2.93 billion OptionableOptionable Beta1.12 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Sven Ante Lundberg M.D. (Age 61)CEO, President & Executive Director Comp: $953.06kMr. Gregory D. Perry (Age 64)Chief Financial Officer Comp: $63.76kMr. Peter B. Silverman J.D. (Age 46)EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal Comp: $601.19kDr. Hui Liu Ph.D. (Age 57)Chief Business Officer, Executive VP & Head of Merus U.S. Comp: $597.7kDr. Andrew Joe M.D. (Age 57)Chief Medical Officer & Senior VP Comp: $692.74kDr. Hennie HoogenboomCo-Founder and Scientific AdvisorHarry ShumanChief Accounting OfficerMr. Cornelis Adriaan de Kruif Ph.D. (Age 59)CTO & Executive VP Comp: $350.85kDr. Cecilia Anna Wilhelmina Geuijen Ph.D.Chief Scientific Officer & Senior VPKathleen FarrenIR & Corporate Communications OfficerMore ExecutivesKey CompetitorsCatalentNYSE:CTLTLegend BiotechNASDAQ:LEGNQiagenNYSE:QGENSummit TherapeuticsNASDAQ:SMMTRoivant SciencesNASDAQ:ROIVView All CompetitorsInsiders & InstitutionsGordian Capital Singapore Pte LtdBought 4,530 shares on 8/30/2024Ownership: 0.008%Novo Holdings A SBought 675,000 shares on 8/20/2024Ownership: 1.150%Driehaus Capital Management LLCBought 323,518 shares on 8/16/2024Ownership: 2.641%Perceptive Advisors LLCBought 300,000 shares on 8/16/2024Ownership: 0.511%Algert Global LLCBought 35,549 shares on 8/16/2024Ownership: 0.227%View All Insider TransactionsView All Institutional Transactions MRUS Stock Analysis - Frequently Asked Questions How have MRUS shares performed this year? Merus' stock was trading at $27.50 at the start of the year. Since then, MRUS shares have increased by 81.8% and is now trading at $50.00. View the best growth stocks for 2024 here. How were Merus' earnings last quarter? Merus (NASDAQ:MRUS) announced its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.76) by $0.05. The biotechnology company had revenue of $7.33 million for the quarter, compared to the consensus estimate of $9.64 million. Merus had a negative trailing twelve-month return on equity of 36.33% and a negative net margin of 476.41%. When did Merus IPO? Merus (MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. Who are Merus' major shareholders? Merus' top institutional shareholders include Deerfield Management Company L.P. Series C (4.68%), Federated Hermes Inc. (4.09%), Samlyn Capital LLC (3.96%) and Driehaus Capital Management LLC (2.64%). Insiders that own company stock include Sven Ante Lundberg, Harry Shuman, Peter B Silverman and Bvf Partners L P/Il. View institutional ownership trends. How do I buy shares of Merus? Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Merus investors own include Pfizer (PFE), Micron Technology (MU), OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Sorrento Therapeutics (SRNE) and Aldeyra Therapeutics (ALDX). This page (NASDAQ:MRUS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.